Bristol-Myers Squibb (NYSE:BMY) Shares Up 0.3%

Bristol-Myers Squibb (NYSE:BMY)’s share price rose 0.3% during mid-day trading on Friday . The company traded as high as $44.33 and last traded at $43.83. Approximately 3,174,975 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 15,808,061 shares. The stock had previously closed at $43.70.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Redburn Atlantic lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $77.00 to $54.00 in a research report on Tuesday, February 6th. BMO Capital Markets dropped their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research report on Friday, April 26th. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Barclays cut their target price on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. Finally, StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday, April 15th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Stock Up 0.7 %

The firm has a 50-day simple moving average of $50.37 and a 200 day simple moving average of $50.74. The stock has a market capitalization of $89.17 billion, a P/E ratio of -14.19, a P/E/G ratio of 14.72 and a beta of 0.45. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The business had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. During the same period last year, the company earned $2.05 EPS. The firm’s revenue was up 4.7% compared to the same quarter last year. On average, equities research analysts forecast that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 5.46%. The ex-dividend date of this dividend was Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Institutional Investors Weigh In On Bristol-Myers Squibb

Several institutional investors and hedge funds have recently made changes to their positions in BMY. OFI Invest Asset Management acquired a new position in shares of Bristol-Myers Squibb in the 3rd quarter worth approximately $25,000. Milestone Investment Advisors LLC acquired a new position in Bristol-Myers Squibb in the third quarter valued at $27,000. Northwest Financial Advisors bought a new stake in Bristol-Myers Squibb during the fourth quarter valued at $27,000. Blue Bell Private Wealth Management LLC grew its holdings in Bristol-Myers Squibb by 61.5% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 200 shares during the period. Finally, Accordant Advisory Group Inc bought a new position in shares of Bristol-Myers Squibb in the 1st quarter worth about $31,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.